Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael K Brawer

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Contemporary Clinical Trials|September 12, 2008
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancerTimothy J Wilt, Michael K Brawer, Michael J Barry, et al.
Urology|October 18, 2002
Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliterWolfgang Horninger, Carol D Cheli, Richard J Babaian, et al.
Urology|October 18, 2002
Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?Yoshio Naya, Thomas A Stamey, Carol D Cheli, et al.
Urology|December 11, 2003
Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancerYoshio Naya, Herbert A Fritsche, Carol D Cheli, et al.
The Journal of Urology|April 17, 2002
Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancerKoji Okihara, Carol D Cheli, Alan W Partin, et al.
The Journal of Urology|October 9, 2003
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trialAlan W Partin, Michael K Brawer, Georg Bartsch, et al.
Urology|October 18, 2002
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosisSamir S Taneja, Elias I Hsu, Carol D Cheli, et al.
The New England Journal of Medicine|July 20, 2012
Radical prostatectomy versus observation for localized prostate cancerTimothy J Wilt, Michael K Brawer, Karen M Jones, et al.
International Journal of Radiation Oncology, Biology, Physics|October 5, 2021
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated RadiationJonathan Tward, Lauren Lenz, Darl D Flake, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Contemporary Clinical Trials|September 12, 2008
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancerTimothy J Wilt, Michael K Brawer, Michael J Barry, et al.
Urology|October 18, 2002
Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliterWolfgang Horninger, Carol D Cheli, Richard J Babaian, et al.
Urology|October 18, 2002
Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?Yoshio Naya, Thomas A Stamey, Carol D Cheli, et al.
Urology|December 11, 2003
Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancerYoshio Naya, Herbert A Fritsche, Carol D Cheli, et al.
The Journal of Urology|April 17, 2002
Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancerKoji Okihara, Carol D Cheli, Alan W Partin, et al.
The Journal of Urology|October 9, 2003
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trialAlan W Partin, Michael K Brawer, Georg Bartsch, et al.
Urology|October 18, 2002
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosisSamir S Taneja, Elias I Hsu, Carol D Cheli, et al.
The New England Journal of Medicine|July 20, 2012
Radical prostatectomy versus observation for localized prostate cancerTimothy J Wilt, Michael K Brawer, Karen M Jones, et al.
International Journal of Radiation Oncology, Biology, Physics|October 5, 2021
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated RadiationJonathan Tward, Lauren Lenz, Darl D Flake, et al.
Pageof 4